Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode.
Primary objective :
- To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
Secondary objectives:
- To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Zagreb, Croatia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Praha, Czech Republic
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Tallinn, Estonia
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Paris, France
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Montenegro, Montenegro
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Gouda, Netherlands
- Sanofi-Aventis Administrative Office
-
-
-
-
-
Belgrade, Serbia
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients suffering from a recurrent major depressive episode of at least moderate intensity (DSM-IV)
- patients have been hospitalized for the treatment of a previous episode, or a previous episode required antidepressant treatment(s)at the recommended dose level for at least 2 months.
- the duration of the current episode is of at least six weeks unless the severity of symptoms justifies shorter duration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
|
oral administration 2 X 350mg/day at 12 hours intervals
|
|
Placebo Comparator: 2
|
oral administration 12 hours intervals
|
|
Active Comparator: 3
|
oral 20 mg/day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change from baseline of the total score of the HAM-D 17 items.
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
clinical global impression (CGI) severity and improvement scores
Time Frame: 6 weeks
|
6 weeks
|
|
patient global impression (PGI) improvement score
Time Frame: 6 weeks
|
6 weeks
|
|
social and occupational functioning assessment scale (SOFAS) score
Time Frame: 6 weeks
|
6 weeks
|
|
HAM-D subscores
Time Frame: 6 weeks
|
6 weeks
|
|
HAM-D responders and remitters
Time Frame: 6 weeks
|
6 weeks
|
|
HAM-A total score and subscores
Time Frame: 6 weeks
|
6 weeks
|
|
MADRS total score
Time Frame: 6 weeks
|
6 weeks
|
|
clinical monitoring of adverse events (AEs)
Time Frame: 6 weeks
|
6 weeks
|
|
laboratory parameters
Time Frame: 6 weeks
|
6 weeks
|
|
electrocardiogram (ECG) parameters, change in vital signs and body weight
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Mood Disorders
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Adrenergic Agonists
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Cytochrome P-450 Enzyme Inhibitors
- Antidepressive Agents, Second-Generation
- Cytochrome P-450 CYP2D6 Inhibitors
- Adrenergic beta-Agonists
- Paroxetine
- Amibegron
Other Study ID Numbers
Other Study ID Numbers
- EFC5374
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.